New — Free Peptide Starter Guide (2026): 13 chapters, 34 cited studies

Get it free
ToolsCompareCartalax vs Ipamorelin

Cartalax vs Ipamorelin

Side-by-side comparison of key properties, dosing, and research.

Anti-Aging & Longevity
Cartalax
Growth Hormone Peptides
Ipamorelin
Summary
Cartalax is a tetrapeptide bioregulator (Ala-Glu-Asp-Pro) developed by Professor Vladimir Khavinson for cartilage and connective tissue. It is tissue-specific for chondrocytes and cartilaginous structures, supporting cartilage matrix synthesis, slowing degenerative changes, and promoting joint longevity. It is used in the context of osteoarthritis, joint aging, and athletic cartilage preservation.
Ipamorelin is a selective GHRP (growth hormone releasing peptide) and one of the cleanest GH secretagogues available. It selectively stimulates GH release without significantly raising cortisol, prolactin, or appetite — making it ideal for long-term use and anti-aging protocols.
Half-Life
Short (minutes); gene-regulatory effects are sustained
2 hours
Admin Route
SubQ, Oral
SubQ
Research
Typical Dose
10 mg per day
100–300 mcg
Frequency
Daily for 10–30 days
Once to twice daily
Key Benefits
  • Supports cartilage matrix synthesis and maintenance
  • May slow progression of osteoarthritic cartilage degradation
  • Reduces chondrocyte apoptosis
  • Promotes joint longevity in aging and high-impact sports
  • Anti-aging effects on connective tissue
  • Complementary to BPC-157 and TB-500 in joint recovery protocols
  • Well tolerated in available human and animal research
  • Increases lean muscle mass
  • Enhances fat loss
  • Improves recovery time
  • Strengthens bones and joints
  • Better sleep quality and REM sleep
  • Enhanced skin elasticity
  • Minimal impact on hunger or cortisol
  • No cortisol or prolactin spike
  • Clean GH release suitable for long-term protocols
Side Effects
  • Generally well tolerated
  • Mild injection site reactions
  • No significant adverse events reported at standard doses
  • Injection site irritation
  • Temporary water retention (mild)
  • Possible hunger increase (milder than GHRP-6)
  • Numbness or tingling in extremities (rare)
Stacks With